Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$18.4 million.

  • Applied Therapeutics' Cash from Operations rose 2112.73% to -$18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.8 million, marking a year-over-year decrease of 611.67%. This contributed to the annual value of -$84.3 million for FY2024, which is 5280.12% down from last year.
  • Applied Therapeutics' Cash from Operations amounted to -$18.4 million in Q3 2025, which was up 2112.73% from -$20.3 million recorded in Q2 2025.
  • Applied Therapeutics' 5-year Cash from Operations high stood at -$7.0 million for Q1 2023, and its period low was -$28.6 million during Q1 2025.
  • In the last 3 years, Applied Therapeutics' Cash from Operations had a median value of -$18.9 million in 2024 and averaged -$18.8 million.
  • As far as peak fluctuations go, Applied Therapeutics' Cash from Operations plummeted by 17054.36% in 2024, and later surged by 2112.73% in 2025.
  • Applied Therapeutics' Cash from Operations (Quarter) stood at -$17.0 million in 2023, then dropped by 14.49% to -$19.5 million in 2024, then rose by 5.49% to -$18.4 million in 2025.
  • Its Cash from Operations was -$18.4 million in Q3 2025, compared to -$20.3 million in Q2 2025 and -$28.6 million in Q1 2025.